Welche Immuntherapien sind heute schon Standard? Und mit welchen Nebenwirkungen muss man bei Immuntherapien rechnen?

Zusammenfassung

Im Vergleich zu früheren Behandlungsstandards (einschl. Chemotherapie, Strahlentherapie und Chirurgie) hat die Immuntherapie bedeutende Verbesserungen für Patienten in Bezug auf Überleben und Lebensqualität gebracht. Immuntherapie ist letztlich eine Art Sammelbegriff für eine Vielzahl unterschiedlichster Therapeutika. Immuntherapeutische Ansätze haben sich fest als ein neuer Pfeiler der Krebsversorgung etabliert, von den neoadjuvanten und adjuvanten Ansätzen bis hin zur metastatischen Phase bei diversen Entitäten. In diesem Review-Artikel heben wir hervor, welche Immuntherapien heutzutage in der onkologischen Versorgung Standard sind, mit einem starken Fokus auf Immuncheckpoint-Inhibitoren (ICIs), deren Einschränkungen sowie häufig auftretenden Nebenwirkungen.

Abstract

In comparison to earlier treatment standards (including chemotherapy, radiation therapy, and surgery), immunotherapy has significantly improved patients’ survival and quality of life. Immunotherapy is ultimately a broad term that encompasses a variety of therapeutics. Immunotherapeutic approaches have firmly established themselves as a new pillar of cancer care, ranging from neoadjuvant and adjuvant strategies to the metastatic phase in various entities. In this review article, we highlight which immunotherapies are currently standard in oncological care, with a strong focus on immune checkpoint inhibitors (ICIs), their limitations, and the commonly occurring side effects.

Schlüsselwörter

Immuntherapie - Immun-Check-Point-Inhibitor - Nebenwirkungen - Viszeralchirurgie

Keywords

immuntherapy - side effects - immune checkpoint inhibitors - visceral surgery

Publikationsverlauf

Eingereicht: 11. November 2024

Angenommen nach Revision: 18. Februar 2025

Artikel online veröffentlicht:
08. April 2025

• Literatur

• 1 McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006; 26: 154-158
• 2 Shankaran V, Ikeda H, Bruce AT. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111
• 3 Dunn GP, Bruce AT, Ikeda H. et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998
• 4 Basudan AM. The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clin Pract 2022; 13: 22-40
• 5 Du S, Yan J, Xue Y. et al. Adoptive cell therapy for cancer treatment. Exploration (Beijing) 2023; 3
• 6 Song K. Current Development Status of Cytokines for Cancer Immunotherapy. Biomol Ther (Seoul) 2024; 32: 13-24
• 7 Hafron JM, Wilfehrt HM, Ferro C. et al. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents. Adv Ther 2022; 39: 2515-2532
• 8 Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect 2019; 7
• 9 Napolitano S, Martini G, Ciardiello D. et al. Targeting the EGFR signalling pathway in metastatic colorectal cancer. Lancet Gastroenterol Hepatol 2024; 9: 664-676
• 10 Albarrán V, San Román M, Pozas J. et al. Adoptive T cell therapy for solid tumors: current landscape and future challenges. Front Immunol 2024; 15
• 11 Lin MJ, Svensson-Arvelund J, Lubitz GS. et al. Cancer vaccines: the next immunotherapy frontier. Nat Cancer 2022; 3: 911-926
• 12 Deckers J, Anbergen T, Hokke AM. et al. Engineering cytokine therapeutics. Nat Rev Bioeng 2023; 1: 286-303
• 13 Chan KK, Bass AR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ 2020; 369: m736
• 14 Freites-Martinez A, Santana N, Arias-Santiago S. et al. Using the Common Terminology Criteria for Adverse Events (CTCAE-Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed) 2021; 112: 90-92
• 15 U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. November 27, 2017. Zugriff am 26. Februar 2025 unter: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5×7.pdf
• 16 Perdigoto AL, Kluger H, Herold KC. Adverse events induced by immune checkpoint inhibitors. Curr Opin Immunol 2021; 69: 29-38
• 17 Postow MA, Chesney J, Pavlick AC. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017
• 18 Martins F, Sofiya L, Sykiotis GP. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16: 563-580
• 19 Mallio CA, Bernetti C, Cea L. et al. Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review. Curr Oncol 2023; 30: 4700-4723
• 20 Peeraphatdit TB, Wang J, Odenwald MA. et al. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology 2020; 72: 315-329
• 21 Michot JM, Bigenwald C, Champiat S. et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer 2016; 54: 139-148
• 22 Nishino M, Ramaiya NH, Awad MM. et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res 2016; 22: 6051-6060
• 23 Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 2021; 17: 389-399
• 24 Shalata W, Abu-Salman A, Steckbeck R. et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers (Basel) 2021; 13: 5218
• 25 Johnson DB, Balko JM, Compton ML. et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 2016; 375: 1749-1755
• 26 Lyon AR, Yousaf N, Battisti NML. et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 2018; 19: e447-e458
• 27 Feng S, Coward J, McCaffrey E. et al. Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. J Thorac Oncol 2017; 12: 1626-1635
• 28 Mikami T, Liaw B, Asada M. et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol 2021; 152: 135-144